This extended evaluation (EE) of the SONICS study assessed effects of levoketoconazole for an additional 6 months following open-label, 6-month maintenance treatment in endogenous Cushing's syndrome.
- Anniversary/History
- Membership
- Publications
- Resources
- Education
- Events
- Advocacy
- Careers
- About
- For Pain Patients and Professionals